CGRP Antagonists: How Anti-CGRP Medications Work for Migraine

Key Takeaways

• Drug class 1: Anti-CGRP monoclonal antibodies — injected or infused, long-acting (weeks to months), FDA-approved for episodic and/or chronic migraine prevention. Four agents approved as of April 2026: erenumab, fremanezumab, galcanezumab, eptinezumab.
• Drug class 2: Gepants (CGRP receptor antagonists) — oral small-molecule agents, shorter-acting, FDA-approved for acute migraine treatment and/or prevention. Four agents approved as of April 2026: rimegepant, ubrogepant, atogepant, zavegepant.
• Mechanism: Both classes block CGRP from activating the CLR/RAMP1 receptor heterodimer on meningeal blood vessel walls and trigeminal neurons, interrupting the vasodilation and neurogenic inflammation that drive migraine pain.
• Efficacy signal: Phase 3 trials show approximately 40–60% of treated patients achieve 50% or greater reduction in monthly migraine days with anti-CGRP monoclonal antibodies; gepants show similar class-level efficacy for acute treatment.
• Mechanism distinction: Monoclonal antibodies bind with very high affinity over weeks, producing functionally sustained blockade; gepants bind reversibly over hours. Monoclonal antibodies target either the ligand or the receptor; gepants target only the receptor.
• As of April 2026: All drugs described are FDA-approved prescription medications. This article covers drug classes, not individual prescribing guidance. Consult a qualified healthcare provider.

How Anti-CGRP Medications Were Developed

The development of anti-CGRP medications followed directly from the basic science of migraine pathophysiology. Once researchers established that CGRP rises during migraine attacks, returns to baseline after successful treatment, and triggers migraine-like attacks when infused into migraine patients, the logic for therapeutic blockade became compelling. The path from that biology to approved drugs took over three decades. Tepper, in a 2018 historical review in Headache, traced the full arc from CGRP discovery to approved drugs, describing how the field moved from receptor characterization to monoclonal antibody development to gepant chemistry.

The first therapeutic attempt to block CGRP was through small-molecule receptor antagonists — the gepant class — beginning with olcegepant and then telcagepant in the early 2000s. Telcagepant showed strong efficacy in acute migraine trials but produced hepatotoxicity signals in longer-duration studies that ended its development. This setback accelerated interest in monoclonal antibodies, which are too large to penetrate the blood-brain barrier (thus acting peripherally) and do not undergo hepatic metabolism — avoiding the liver safety concern that complicated telcagepant. Parallel to antibody development, chemists returned to gepant design with structural modifications that eliminated the hepatotoxicity signal, producing the second-generation agents now approved.

Anti-CGRP Monoclonal Antibodies: The Preventive Class

Mechanism and route

Anti-CGRP monoclonal antibodies are humanized or fully human immunoglobulin G (IgG) antibodies designed to bind either the CGRP peptide (fremanezumab, galcanezumab, eptinezumab) or its receptor — specifically the CLR component of the CLR/RAMP1 heterodimer (erenumab). The distinction between ligand-targeting and receptor-targeting antibodies is mechanistically meaningful: ligand-targeting antibodies sequester free CGRP in plasma and tissue, preventing it from reaching the receptor; receptor-targeting antibodies block the receptor site regardless of local CGRP concentration. These two mechanistic subclasses — ligand-targeting and receptor-targeting antibodies — have distinct potential clinical implications. The monoclonal antibodies are administered subcutaneously (for self-injection by the patient at home, monthly or quarterly depending on agent) or intravenously (quarterly, for eptinezumab, administered in a clinical setting). Their half-lives of 20–50 days produce sustained CGRP pathway blockade between doses.

Efficacy at the class level

The class-level efficacy of anti-CGRP monoclonal antibodies is now established across multiple independent trials and meta-analyses. The 2022 European Headache Federation guideline by Sacco and colleagues in The Journal of Headache and Pain applied GRADE methodology to rate the quality of evidence for each approved monoclonal antibody, confirming statistically significant reductions in monthly migraine days compared with placebo in both episodic and chronic migraine populations. Barbanti and colleagues, in a 2022 multicenter prospective study of 864 migraine patients in The Journal of Headache and Pain, reported response rates across 50%, 75%, and 100% response categories, with approximately 40–60% of participants achieving at least a 50% reduction in monthly migraine days. Contemporary reviews continue to report efficacy data for approved monoclonal antibodies in episodic migraine.

An important clinical benefit documented in patients with medication-overuse headache — a condition in which overuse of acute migraine medications transforms episodic migraine into a chronic daily pattern — has been reported across real-world observational studies of anti-CGRP monoclonal antibodies in chronic migraine populations. These findings are reported in the post-marketing observational literature rather than in the pivotal phase 3 trials that supported FDA approval; medication-overuse headache is not an FDA-labeled indication for any anti-CGRP mAb. Readers interested in this evidence should consult current review literature (for example, Sacco and colleagues' 2022 European Headache Federation guideline).

Guideline status

European Headache Federation clinical guidelines, updated by Sacco and colleagues in a 2022 paper in The Journal of Headache and Pain, positioned anti-CGRP monoclonal antibodies as a first-line preventive option for patients with episodic and chronic migraine who have not responded adequately to, or cannot tolerate, conventional preventive options; recent guideline updates have extended similar recognition to gepants approved for prevention. Earlier foundational guidelines by Sacco and colleagues published in 2019 established the evidence basis and patient selection criteria for the monoclonal antibody class. A 12-week trial period is the standard recommendation before evaluating therapeutic response.

Adverse effects at the class level

Anti-CGRP monoclonal antibodies are generally well-tolerated in clinical trials, with adverse event profiles broadly similar to placebo in most studies. Common adverse effects at the class level include injection site reactions (erythema, pain, induration), constipation, and fatigue. Some patients report worsening hypertension with erenumab specifically. Given CGRP's role in vasodilation and cardiovascular regulation, post-marketing pharmacovigilance continues to monitor potential cardiovascular signals, particularly in patients with pre-existing cardiovascular disease. Pregnancy safety data are limited, and these agents are generally not recommended during pregnancy or lactation.

Gepants (CGRP Receptor Antagonists): The Oral Class

Mechanism and route

Gepants are small-molecule, orally bioavailable antagonists of the CGRP receptor. Unlike monoclonal antibodies, gepants bind the CLR/RAMP1 receptor reversibly — they compete with CGRP for the receptor site and dissociate over hours, rather than occupying the receptor for weeks. This reversible binding explains their suitability for acute treatment (rapid onset, returns to baseline within hours) and, for some agents at regular preventive doses, prevention. The oral route is a practical advantage for many patients compared to injectable monoclonal antibodies. Moreno-Ajona, Pérez-Rodríguez, and Goadsby, writing in Current Opinion in Neurology in 2020, described the gepant class and its mechanistic distinction from the monoclonal antibody class.

Gepants do not cross the blood-brain barrier in meaningful quantities under normal physiological conditions, meaning their primary site of action is peripheral — consistent with the emerging understanding that peripheral CGRP blockade is sufficient to produce migraine relief in most patients. Edvinsson, writing in British Journal of Pharmacology in 2008, reviewed the evidence supporting peripheral CGRP as the primary therapeutic target, which underpins the mechanistic design of both drug classes.

Efficacy at the class level

Rissardo and Caprara, in a 2022 narrative review in Brain Sciences, reviewed rimegepant, ubrogepant, and zavegepant with their respective efficacy and safety data across acute and preventive indications. In phase 3 acute migraine trials, gepants produced meaningful rates of pain freedom at 2 hours compared with placebo. Rimegepant carries a unique dual approval for both acute treatment (75 mg as needed) and prevention (75 mg every other day) — the only oral migraine medication approved for both indications. Pellesi and colleagues, in a 2025 review in Pain Management, provided head-to-head comparisons across ubrogepant, rimegepant, and zavegepant, offering recent head-to-head comparative gepant data.

Adverse effects at the class level

Second-generation gepants do not produce the hepatotoxicity that ended telcagepant's development. Rissardo and Caprara in 2022 reviewed the safety profiles of approved gepants and confirmed the absence of significant liver enzyme elevations in clinical trial data. Common adverse effects at the class level include nausea and dizziness. Rimegepant and other gepants metabolized by CYP3A4 have drug interaction potential with strong CYP3A4 inhibitors and inducers; patients taking such medications should discuss this with their provider. Gepants are generally not recommended during pregnancy due to limited safety data.

Comparative effectiveness between gepants

Comparative efficacy and safety data across the FDA-approved anti-CGRP agents for migraine prevention are summarized in current review literature; no single agent has demonstrated clear superiority across all endpoints. Supporting efficacy evidence for the gepant class alongside monoclonal antibody data is documented in phase 3 trial reports and post-marketing studies. Head-to-head randomized trials between individual gepants are limited; most comparative data comes from network meta-analyses and observational studies.

Comparing the Two Classes

Patients and providers often ask how to choose between anti-CGRP monoclonal antibodies and gepants. The two classes are not head-to-head competitors but rather complements that differ in route, duration, indication type, and practical considerations.

• Route of administration: Monoclonal antibodies require subcutaneous injection or intravenous infusion; gepants are oral tablets or a nasal spray.
• Duration of action: Monoclonal antibodies provide weeks-to-months of sustained blockade per dose; gepants act over hours.
• Primary indication: Monoclonal antibodies are approved for prevention only; gepants are approved for acute treatment, with some additionally approved for prevention.
• Mechanism binding type: Monoclonal antibodies bind CGRP or its receptor with very high affinity; gepants bind reversibly.
• Target (ligand vs. receptor): Some monoclonal antibodies target the CGRP ligand; gepants and erenumab target the receptor.
• Drug interactions: Gepants have CYP3A4 interaction potential; monoclonal antibodies do not undergo hepatic metabolism and have fewer drug-drug interactions.

The Sacco 2022 European Headache Federation guideline in The Journal of Headache and Pain provides one of the most comprehensive comparative evidence bases currently available across both classes. In real-world settings, experience with CGRP-targeted antibodies from specialized headache centers has broadly confirmed the efficacy signals reported in phase 3 trials. Response to CGRP antagonist treatment varies across migraine phenotypes, and ongoing research is exploring predictors of differential response, suggesting that pharmacogenomic factors may eventually guide therapy selection.

Reducing CGRP: Non-Pharmacological Considerations

Many patients ask whether lifestyle changes can reduce CGRP activity independent of medication. The evidence for non-pharmacological approaches is limited compared with the clinical trial evidence for approved medications, but it is not entirely absent.

Current research literature describes several non-pharmacological factors associated with migraine frequency and, in some cases, with CGRP activity. Aerobic exercise has been associated with reduced migraine frequency in observational populations; stress is a well-established migraine trigger; sleep disruption is both a trigger and a consequence of migraine; and dietary factors including alcohol, tyramine-containing foods, and caffeine have been implicated as triggers in susceptible individuals. Whether these effects operate specifically through CGRP pathways versus other physiological mechanisms remains an area of investigation.

These lifestyle considerations are not substitutes for pharmacological management in established migraine disorders. They are best understood as complementary factors to discuss with a provider in the context of a broader management plan. The degree to which these effects operate specifically through CGRP modulation versus other physiological pathways is not yet established.

Which Biomarkers Are Worth Testing?

Before initiating anti-CGRP preventive therapy, providers typically assess baseline health markers to establish context, screen for contraindications, and provide reference points for monitoring. Plasma CGRP itself is not a standard clinical test for guiding treatment decisions — drug prescribing is based on clinical criteria rather than measured CGRP levels.

• TSH (Thyroid-Stimulating Hormone)
  • What it shows: Thyroid function; both hypothyroidism and hyperthyroidism can worsen or mimic migraine.
  • Why it is relevant: Thyroid dysfunction is among the most common reversible secondary contributors to escalating headache frequency; ruling it out before attributing all headache to migraine is appropriate clinical practice.
• hs-CRP
  • What it shows: Systemic low-grade inflammation, which may intersect with neuroinflammatory processes relevant to migraine chronification.
  • Why it is relevant: Baseline inflammatory assessment provides context for monitoring over time and may identify concurrent inflammatory conditions that contribute to symptom burden.
• Complete Blood Count (CBC)
  • What it shows: Red blood cell counts, hemoglobin, white blood cells, and platelets.
  • Why it is relevant: Anemia is a common secondary contributor to headache disorders; establishing a pre-treatment CBC provides a baseline for monitoring and rules out hematologic secondary causes.
• Basic Metabolic Panel (BMP)
  • What it shows: Kidney function, electrolytes, and glucose.
  • Why it is relevant: Kidney function assessment is standard before initiating any new preventive medication; electrolyte disturbances (hyponatremia, in particular) can themselves cause headache.
• Liver function tests (ALT, AST)
  • What it shows: Hepatocellular integrity; relevant given the hepatotoxicity history of first-generation gepants.
  • Why it is relevant: A baseline liver enzyme assessment before initiating gepants is clinically reasonable, particularly in patients with pre-existing hepatic conditions or on hepatically metabolized medications. Second-generation gepants have not demonstrated hepatotoxicity, but baseline assessment remains standard clinical practice for any new medication with hepatic metabolism.

Reference ranges vary by lab and individual characteristics. Your provider will interpret your specific results in context.

Understanding Your Treatment Landscape

Anti-CGRP therapy is the first preventive drug class developed specifically for migraine based on its underlying biology, rather than repurposed from another indication. The efficacy evidence across both classes is substantial, and the clinical guideline support is now well-established. That said, no single treatment works for all patients, and the choice between preventive and acute strategies, between monoclonal antibodies and gepants, and between individual agents within those classes involves individualized clinical judgment.

Understanding the biomarkers that provide context for that conversation — thyroid status, inflammatory markers, metabolic baselines — creates a more durable foundation for working with a provider than symptom diaries alone. That approach, measuring what can be measured to inform what cannot be assumed, reflects Superpower's approach to preventive health: objective biology, not guesswork, as the starting point for clinical decisions.

IMPORTANT SAFETY INFORMATION

This article discusses drug classes that target CGRP at the class level for educational purposes only. Superpower Health does not prescribe, sell, or facilitate access to any of the medications described. The drug classes discussed — anti-CGRP monoclonal antibodies and gepants — are FDA-approved prescription medications that require evaluation and prescription by a licensed healthcare provider. This content does not constitute medical advice, diagnosis, or treatment recommendations.

Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab): As of April 2026, these are FDA-approved for the preventive treatment of episodic or chronic migraine in adults, administered by subcutaneous injection or intravenous infusion monthly or quarterly. Common adverse effects at the class level include injection site reactions, constipation, and fatigue. Not recommended during pregnancy; consult your provider about individual risk factors, including cardiovascular disease, before initiating.

Gepants (rimegepant, ubrogepant, atogepant, zavegepant): As of April 2026, these are FDA-approved for acute migraine treatment and/or prevention in adults, administered orally or intranasally. Common adverse effects at the class level include nausea and dizziness. Drug interactions are possible with strong CYP3A4 inhibitors and inducers; consult your provider and pharmacist. Not recommended during pregnancy. Second-generation gepants have not demonstrated the hepatotoxicity associated with first-generation gepants (telcagepant) in clinical trial data; however, patients with significant hepatic impairment should discuss suitability with their provider.

This article was reviewed for medical accuracy by [Reviewer Name, MD/DO/NP], Superpower Medical Advisory Team — [Month Year]. It does not replace consultation with a qualified clinician who can evaluate your individual health history, current medications, and clinical picture.

Disclaimer: IMPORTANT: This article discusses prescription drug classes targeting CGRP for educational purposes only. Superpower Health does not prescribe, sell, or facilitate access to anti-CGRP therapies. Always consult a qualified healthcare provider. This page is provided for educational and informational purposes only.